BOLD

Boundless Bio
BOLD

$5.41
13.42%
 

About: Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 72

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

20,778,197,900% more capital invested

Capital invested by funds: $0 [Q4 2023] → $208M (+$208M) [Q1 2024]

4,200% more funds holding

Funds holding: 0 [Q4 2023] → 42 (+42) [Q1 2024]

4,200% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 0

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$20
270%
upside
Avg. target
$23
325%
upside
High target
$25
362%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Leerink Partners
Michael Cherny
362%upside
$25
Outperform
Initiated
22 Apr 2024
Guggenheim
Yige Guo
344%upside
$24
Buy
Initiated
22 Apr 2024
Piper Sandler
Joseph Catanzaro
270%upside
$20
Overweight
Initiated
22 Apr 2024

Financial journalist opinion